Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes

Journal of the American Heart Association

Volumn 3, Issue 6, 2014, Pages

  Tanaka, Atsushi ^a,b   Yuasa, Shinsuke ^a   Mearini, Giulia ^d,e   Egashira, Toru ^a   Seki, Tomohisa ^a   Kodaira, Masaki ^a   Kusumoto, Dai ^a   Kuroda, Yusuke ^a   Okata, Shinichiro ^c   Suzuki, Tomoyuki ^a   Inohara, Taku ^a   Arimura, Takuro ^c   Makino, Shinji ^a   Kimura, Kensuke ^a   Kimura, Akinori ^c   Furukawa, Tetsushi ^c   Carrier, Lucie ^d,e   Node, Koichi ^b   Fukuda, Keiichi ^a  

^a KEIO UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Disease modeling; ET 1; HCM; IPS cells; MYBPC3

Indexed keywords

ENDOTHELIN 1; MYOSIN HEAVY CHAIN BETA; PROTEIN MYBPC3; UNCLASSIFIED DRUG; CARRIER PROTEIN; MYOSIN-BINDING PROTEIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE REPORT; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE COURSE; EMBRYO; GENOTYPE ENVIRONMENT INTERACTION; HEART MUSCLE CELL; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERTROPHIC CARDIOMYOPATHY; MOUSE; MUSCLE CONTRACTION; MUSCLE FIBRIL; NEWBORN; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; VIDEORECORDING; ANIMAL; BIOMECHANICS; CARDIOMEGALY; CASE CONTROL STUDY; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; GENOTYPE; HEART CONTRACTION; HEART VENTRICLE FUNCTION; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; SCID MOUSE; SIGNAL TRANSDUCTION; TIME; TRANSGENIC MOUSE;

ANIMALS; BIOMECHANICAL PHENOMENA; CARDIOMEGALY; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; GENE-ENVIRONMENT INTERACTION; GENOTYPE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; MYOFIBRILS; PHENOTYPE; RISK FACTORS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; VENTRICULAR DYSFUNCTION; VIDEO RECORDING;

EID: 84925833680     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001263     Document Type: Article

References (47)

1. Members WC, Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2761-2796.
2. Coats CJ, Hollman A. Hypertrophic cardiomyopathy: lessons from history. Heart. 2008;94:1258-1263.
3. Ashrafian H, McKenna WJ, Watkins H. Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. Circ Res. 2011;109:86-96.
4. McConnell BK, Fatkin D, Semsarian C, Jones KA, Georgakopoulos D, Maguire CT, Healey MJ, Mudd JO, Moskowitz IPG, Conner DA, Giewat M, Wakimoto H, Berul CI, Schoen FJ, Kass DA, Seidman CE, Seidman JG. Comparison of two murine models of familial hypertrophic cardiomyopathy. Circ Res. 2001;88:383-389.
5. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet. 2000;355:58-60.
6. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-872.
7. Khan JM, Lyon AR, Harding SE. The case for induced pluripotent stem cellderived cardiomyocytes in pharmacological screening. Br J Pharmacol. 2013;169:304-317.
8. Tiscornia G, Vivas EL, Belmonte JCI. Diseases in a dish: modeling human genetic disorders using induced pluripotent cells. Nat Med. 2011;17:1570-1576.
9. Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B, Anderson ME, Boineau R, Byrne BJ, Cappola TP, Kalluri R, LeWinter MM, Maron MS, Molkentin JD, Ommen SR, Regnier M, Tang WHW, Tian R, Konstam MA, Maron BJ, Seidman CE. Research priorities in hypertrophic cardiomyopathy. Circulation. 2010;122:1130-1133.
10. Behrens-Gawlik V, Mearini G, Gedicke-Hornung C, Richard P, Carrier L. MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNAbased correction. Pflugers Arch. 2014;466:215-223.
11. Marian AJ. Experimental therapies in hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2009;2:483-492.
12. Hayakawa T, Kunihiro T, Dowaki S, Uno H, Matsui E, Uchida M, Kobayashi S, Yasuda A, Shimizu T, Okano T. Noninvasive evaluation of contractile behavior of cardiomyocyte monolayers based on motion vector analysis. Tissue Eng Part C Methods. 2012;18:21-32.
13. Ohnuki M, Takahashi K, Yamanaka S. Generation and characterization of human induced pluripotent stem cells. Curr Protoc Stem Cell Biol. John Wiley & Sons, Inc; 2009;9:4A.2. 1-25.
14. Seki T, Yuasa S, Fukuda K. Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus. Nat Protoc. 2012;7:718-728.
15. Seki T, Yuasa S, Fukuda K. Derivation of induced pluripotent stem cells from human peripheral circulating T cells. Curr Protoc Stem Cell Biol. John Wiley & Sons, Inc; 2011;18:4A.3. 1-9.
16. Vignier N, Schlossarek S, Fraysse B, Mearini G, Krämer E, Pointu H, Mougenot N, Guiard J, Reimer R, Hohenberg H, Schwartz K, Vernet M, Eschenhagen T, Carrier L. Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ Res. 2009;105:239-248.
17. Seki T, Yuasa S, Oda M, Egashira T, Yae K, Kusumoto D, Nakata H, Tohyama S, Hashimoto H, Kodaira M, Okada Y, Seimiya H, Fusaki N, Hasegawa M, Fukuda K. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell. 2010;7:11-14.
18. Egashira T, Yuasa S, Suzuki T, Aizawa Y, Yamakawa H, Matsuhashi T, Ohno Y, Tohyama S, Okata S, Seki T, Kuroda Y, Yae K, Hashimoto H, Tanaka T, Hattori F, Sato T, Miyoshi S, Takatsuki S, Murata M, Kurokawa J, Furukawa T, Makita N, Aiba T, Shimizu W, Horie M, Kamiya K, Kodama I, Ogawa S, Fukuda K. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc Res. 2012;95:419-429.
19. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol. 1981;48:418-428.
20. Tashiro A, Masuda T, Segawa I. Morphometric comparison of mitochondria and myofibrils of cardiomyocytes between hypertrophic and dilated cardiomyopathies. Virchows Arch A Pathol Anat Histopathol. 1990;416:473-478.
21. Pearce PC, Hawkey C, Symons C, Olsen EG. Role of calcium in the induction of cardiac hypertrophy and myofibrillar disarray. Experimental studies of a possible cause of hypertrophic cardiomyopathy. Br Heart J. 1985;54:420-427.
22. Kim SJ, Iizuka K, Kelly RA, Geng YJ, Bishop SP, Yang G, Kudej A, McConnell BK, Seidman CE, Seidman JG, Vatner SF. An alpha-cardiac myosin heavy chain gene mutation impairs contraction and relaxation function of cardiac myocytes. Am J Physiol. 1999;276:H1780-H1787.
23. van Dijk SJ, Dooijes D, dos Remedios C, Michels M, Lamers JMJ, Winegrad S, Schlossarek S, Carrier L, ten Cate FJ, Stienen GJM, van der Velden J. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 2009;119:1473-1483.
24. Marston S, Copeland ON, Gehmlich K, Schlossarek S, Carrrier L. How do MYBPC3 mutations cause hypertrophic cardiomyopathy? J Muscle Res Cell Motil. 2012;33:75-80.
25. Poirier O, Nicaud V, McDonagh T, Dargie HJ, Desnos M, Dorent R, Roizes G, Schwartz K, Tiret L, Komajda M, Cambien F. Polymorphisms of genes of the cardiac calcineurin pathway and cardiac hypertrophy. Eur J Hum Genet. 2003;11:659-664.
26. Jandeleit-Dahm KAM, Watson AMD. The endothelin system and endothelin receptor antagonists. Curr Opin Nephrol Hypertens. 2012;21:66-71.
27. 2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol. 2012;52:1299-1307.
28. Molkentin JD. Parsing good versus bad signaling pathways in the heart: role of calcineurin-nuclear factor of activated T-cells. Circ Res. 2013;113:16-19.
29. Wilkins BJ, Dai Y-S, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004;94:110-118.
30. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001;33:655-670.
31. Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J Clin Invest. 1998;102:1292-1300.
32. Kirschner SE, Becker E, Antognozzi M, Kubis H-P, Francino A, Navarro-López F, Bit-Avragim N, Perrot A, Mirrakhimov MM, Osterziel K-J, McKenna WJ, Brenner B, Kraft T. Hypertrophic cardiomyopathy-related β-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells. Am J Physiol. 2005;288:H1242-H1251.
33. Kang M, Chung KY, Walker JW. G-protein coupled receptor signaling in myocardium: not for the faint of heart. Physiology. 2007;22:174-184.
34. Sugden PH. An overview of endothelin signaling in the cardiac myocyte. J Mol Cell Cardiol. 2003;35:871-886.
35. Molkentin JD, Lu J-R, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
36. Wilkins BJ, Molkentin JD. Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol. 2002;541:1-8.
37. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp TJ. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104:e30-e41.
38. Seki T, Yuasa S, Kusumoto D, Kunitomi A, Saito Y, Tohyama S, Yae K, Kishino Y, Okada M, Hashimoto H, Takei M, Egashira T, Kodaira M, Kuroda Y, Tanaka A, Okata S, Suzuki T, Murata M, Fujita J, Fukuda K. Generation and characterization of functional cardiomyocytes derived from human T cell-derived induced pluripotent stem cells. PLoS One. 2014;9:e85645.
39. Östman-Smith I, Wettrell G. Pathophysiology of hypertrophic cardiomyopathy. Lancet. 2000;355:928.
40. Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto T, Nitta M, Taniguchi K, Marumo F. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res. 1991;69:209-215.
41. Hasegawa K, Fujiwara H, Koshiji M, Inada T, Ohtani S, Doyama K, Tanaka M, Matsumori A, Fujiwara T, Shirakami G, Hosoda K, Nakao K, Sasayama S. Endothelin-1 and its receptor in hypertrophic cardiomyopathy. Hypertension. 1996;27:259-264.
42. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41:851-876.
43. 2+ release is a nexus for hypertrophic signaling in cardiac myocytes. Mol Cell. 2009;33:472-482.
44. Thibault G, Arguin C, Garcia R. Cardiac endothelin-1 content and receptor subtype in spontaneously hypertensive rats. J Mol Cell Cardiol. 1995;27:2327-2336.
45. Ito H, Hiroe M, Hirata Y, Fujisaki H, Adachi S, Akimoto H, Ohta Y, Marumo F. Endothelin eta receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation. 1994;89:2198-2203.
46. Ehmke H, Faulhaber J, Münter K, Kirchengast M, Wiesner RJ. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension. 1999;33:954-960.
47. Nagueh SF, Chen S, Patel R, Tsybouleva N, Lutucuta S, Kopelen HA, Zoghbi WA, Quiñones MA, Roberts R, Marian AJ. Evolution of expression of cardiac phenotypes over a 4-year period in the b-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2004;36:663-673.